Abstract
Hepatocarcinogenesis is a multi-step process characterized by progressive cellular and molecular dedifferentiation of hepatocytes and culminating in the emergence of hepatocellular carcinoma (HCC). Knowledge of hepatocarcinogenesis is important because familiarity with the associated imaging features can lead to improved diagnosis of HCC at its early stages. The article reviews the alterations that accumulate leading to HCC result in abnormal imaging features, many of which are included in LI-RADS v2017 as major and ancillary features.
Similar content being viewed by others
References
Tarlow BD, Pelz C, Naugler WE, et al. (2014) Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. Cell Stem Cell 15:605–618
Sia D, Villanueva A, Friedman SL, Llovet JM (2016) Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. https://doi.org/10.1053/j.gastro.2016.11.048
Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674–687
El-Serag HB, Kanwal F (2014) Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology 60:1767–1775
International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49:658–664
Kim CK, Lim JH, Park CK, et al. (2005) Neoangiogenesis and sinusoidal capillarization in hepatocellular carcinoma: correlation between dynamic CT and density of tumor microvessels. Radiology 237:529–534
Ishigami K, Yoshimitsu K, Nishihara Y, et al. (2009) Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology 250:435–443
Santillan C, Fowler K, Kono Y, Chernyak V (2017) LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdom Radiol. https://doi.org/10.1007/s00261-017-1291-4
Marrero JA, Hussain HK, Nghiem HV, et al. (2005) Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 11:281–289
Kitao A, Matsui O, Yoneda N, et al. (2011) The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 21:2056–2066
Chernyak V, Tang A, Flusberg M, et al. (2017) LI-RADS ancillary features on CT and MRI. Abdom Radiol. https://doi.org/10.1007/s00261-017-1220-6
Kitao A, Zen Y, Matsui O, Gabata T, Nakanuma Y (2009) Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography—radiologic-pathologic correlation. Radiology 252:605–614
Matsui O, Kobayashi S, Sanada J, et al. (2011) Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging 36:264–272
Stevens WR, Gulino SP, Batts KP, Stephens DH, Johnson CD (1996) Mosaic pattern of hepatocellular carcinoma: histologic basis for a characteristic CT appearance. J Comput Assist Tomogr 20:337–342
Park YN, Kim Y-B, Yang KM, Park C (2000) Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 124:1061–1065
Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M (2017) Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 33:282–289
Salomao M, Remotti H, Vaughan R, et al. (2012) The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 43:737–746
Zhang J, Krinsky GA (2004) Iron-containing nodules of cirrhosis. NMR Biomed 17:459–464
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study was not supported by a grant.
Conflicts of interest
Kazim Narsinh declares that he has no conflict of interest. Jennifer Cui declares that she has no conflict of interest. Demetri Papadatos declares that he has no conflict of interest. Claude Sirlin receives grant funding from Bayer, Guerbet, Siemens, General Electric, Supersonic, and Arterys. He has consulting and service agreements with Alexion, AstraZeneca, Bioclinica, BMS, Bracco, Celgene, Fibrogen, Galmed, Genentech, Genzyme, Gilead, Icon, Intercept, Isis, Janssen, NuSirt, Perspectum, Pfizer, Profil, Sanofi, Shire, Synageva, Tobira, Takeda, and Virtual Scopics. Cynthia Santillan declares that she has no conflict of interest.
Ethical approval
This article does not contain any studies with human participants performed by any of the authors.
Rights and permissions
About this article
Cite this article
Narsinh, K.H., Cui, J., Papadatos, D. et al. Hepatocarcinogenesis and LI-RADS. Abdom Radiol 43, 158–168 (2018). https://doi.org/10.1007/s00261-017-1409-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-017-1409-8